Vera-Badillo Francisco E, Napoleone Marc, Ocana Alberto, Templeton Arnoud J, Seruga Bostjan, Al-Mubarak Mustafa, AlHashem Hashem, Tannock Ian F, Amir Eitan
Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada,
Breast Cancer Res Treat. 2014 Jul;146(2):235-44. doi: 10.1007/s10549-014-3018-3. Epub 2014 Jun 14.
Women with multifocal or multicentric breast tumors (multifocality henceforth) have been reported to have greater probability of nodal metastasis and relapse and worse survival than women with unifocal tumors. However, these associations have been inconsistent and multifocality is not taken into account by staging guidelines and prognostic models. A systematic review of electronic databases identified publications exploring the association between multifocality and overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and loco-regional relapse (LRR). The hazard ratios (HRs) for OS and DFS for multifocal compared to unifocal tumors were extracted from multivariable analyses and included in a meta-analysis. For studies not reporting multivariable analyses, odds ratios (OR) were estimated from Kaplan-Meier curves for all endpoints at 5 and 10 years. Twenty-two studies comprising 67,557 women were included. Multifocality was reported in 9.5 % of patients. Classical prognostic factors were well balanced between unifocal and multifocal populations. In multivariable analyses, multifocality was associated with significantly worse OS (HR 1.65; P = 0.02), and a non-significant association with worse DFS (HR 1.96; P = 0.07). In univariable analyses, multifocality was associated with worse OS, DFS, DSS, and LRR at 5 years (OR 1.39, P = 0.02; OR 1.52, P = 0.02; OR 1.56, P = 0.03; and OR 3.23, P = 0.02, respectively). Similar estimates were observed at 10 years, but statistical significance was only reached for DSS and LRR. Mutifocality appears to be associated with a worse prognosis, however, substantial inter-study heterogeneity limits the precise determination of increased risk. Further validation of the independent prognostic impact of multifocality is warranted.
据报道,与单灶性乳腺肿瘤患者相比,多灶性或多中心性乳腺肿瘤(以下简称多灶性)患者发生淋巴结转移和复发的可能性更大,生存率更低。然而,这些关联并不一致,分期指南和预后模型并未考虑多灶性因素。一项对电子数据库的系统综述确定了探索多灶性与总生存期(OS)、无病生存期(DFS)、疾病特异性生存期(DSS)和局部区域复发(LRR)之间关联的出版物。从多变量分析中提取多灶性肿瘤与单灶性肿瘤相比的OS和DFS风险比(HR),并纳入荟萃分析。对于未报告多变量分析的研究,从5年和10年时所有终点的Kaplan-Meier曲线估计比值比(OR)。纳入了22项研究,共67557名女性。9.5%的患者报告有多灶性。单灶性和多灶性人群之间的经典预后因素分布均衡。在多变量分析中,多灶性与显著更差的OS相关(HR 1.65;P = 0.02),与更差的DFS有非显著关联(HR 1.96;P = 0.07)。在单变量分析中,多灶性与第5年时更差的OS、DFS、DSS和LRR相关(OR分别为1.39,P = 0.02;OR 1.52,P = 0.02;OR 1.56,P = 0.03;OR 3.23,P = 0.02)。在第10年观察到类似的估计值,但仅DSS和LRR达到统计学显著性。多灶性似乎与更差的预后相关,然而,研究间的显著异质性限制了对风险增加的精确测定。多灶性独立预后影响的进一步验证是必要的。